@article {MacaveiP3055, author = {Vladimir Macavei and Catherine Hyams and Jakir Ullah and Terry O{\textquoteright}Shaughnessy and Veronica White and Jessica Potter and Nivenka Jayasekera and Heinke Kunst}, title = {Treatment for latent tuberculosis infection in migrants carries a low risk of hepatotoxicity}, volume = {44}, number = {Suppl 58}, elocation-id = {P3055}, year = {2014}, publisher = {European Respiratory Society}, abstract = {Background: Identifying and treating people with latent tuberculosis infection(LTBI) in migrants who are at risk of reactivation are critical to reduce the rates of active TB. There have been concerns of treating LTBI in primary care in view of side-effects and in particular the risk of hepatotoxicity.Methods: A retrospective study was conducted at the Newham Chest Clinic in London, U.K. between 1st January 2009 and 31st December 2012. Records of all patients who have been in the country {\guilsinglleft} 5 years and received chemoprophylaxis for LTBI were examined. Patient characteristics, details of anti-tuberculous treatment(ATT) and side-effects were recorded. Blood results including liver function tests(ALT and Bilirubin) before and after treatment were recorded and the need for hospitalisation due to side-effects of ATT.Results: 233 patients with LTBI who were treated with Rifampicin and Isoniazid were included. Mean age was 31{\textpm}5.9 years and 60.7\%(141) were males. 75.5\%(176) patients were from the Indian subcontinent and 24.5\%(57) patients from Africa. 3 patients had hepatitis B. From 17 patients(7.2\%) who experienced side-effects, 5(2.1\%) reported gastrointestinal symptoms(nausea, vomiting), 2(0.8\%) cases of hypersensitivity reaction(pruritus) and 1(0.4\%) case of thrombocytopenia. Drug induced hepatitis with a rise in ALT greater than 3 times normal was present in 9 patients(3.8\%)(p=0.001). An increase in bilirubin greater than 2 times normal was recorded in 3 patients(1.2\%). One patient who also had hepatitis B was hospitalised due to hepatotoxicity.Conclusion: Treatment for LTBI in migrants is safe and is associated with a low risk of hepatotoxicity and should be feasible in primary care.}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/44/Suppl_58/P3055}, eprint = {https://erj.ersjournals.com/content}, journal = {European Respiratory Journal} }